Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule

Novartis provides update on production of radioligand therapy medicines

Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

ESMO (European Society of Medical Oncology) Congress

ASCO (American Society of Clinical Oncology) Annual Meeting

19th Annual ENETS Conference

ASCO Genitourinary Cancers Symposium

ASCO Gastrointestinal Cancers Symposium

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021